ClinicaliQ Trial Snapshot
- A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis — Recruiting • Phase II • Oncology • NCT07501702.
- Intervention: Povetacicept is being tested as a novel treatment for generalized myasthenia gravis (gMG), with evaluation focused on its pharmacodynamic effects, safety profile, and tolerability in adult patients.
- Patient Eligibility: The study targets adults with confirmed generalized myasthenia gravis, representing the patient population most affected by disease-related functional impairment across multiple muscle groups.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
Eligibility Snapshot
- Key Inclusion Criteria: * Age 18-80 years * Diagnosis of generalized myasthenia gravis with generalized muscle weakness and fitting MGFA clinical classification II-IV * Additional inclusion criteria are defined in the protocol Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.